NCT05372016已完成3 期
A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged16-26 Years
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,200
- 试验地点
- 1
- 主要终点
- The seroconversion rate of neutralizing antibodies
研究概览
简要总结
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
盲法说明
Double (Participant, Investigator)
入排标准
- 年龄范围
- 16 Years 至 26 Years（Child, Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •(If the "*" option is not met during screening, the visit can be rescheduled)
- •Chinese women aged 16-26 who can provide legal identification(If the subject is under 18 years old, proof of legal guardian's identity is also required);
- •The subject agreed to participate in the study, and voluntarily signs the informed consent;for subjects aged 16-18 years, they and their legal guardian(s) are supposed to understand and sign informed consent form together； supposed to understand and sign informed consent form together
- •Subjects are able to understand the study procedures and participate in follow-up according to the study requirements;
- •When the subjects were enrolled, the urine pregnancy test was negative, they were not in the lactation period and had no family planning within 7 months after enrollment.2 weeks before included in the study, effective contraceptive measures has been adopted and agreed to in the first seven months after the study (vaccinations after 1 months ago) continue to adopt effective contraceptive measures (effective contraceptive measures including the pill or condoms, etc ); 5.
- •Have an acute illness or an acute episode of a chronic illness within 3 days prior to vaccination or the use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.);
- •*body temperature <37.3# (underarm body temperature)
排除标准
- •First dose exclusion criteria(If the "*" option is met during screening, the visit can be rescheduled)
- •Have been vaccinated with commercially available HPV vaccine in the past or planned to be vaccinated with commercially available HPV vaccine during the study period;Or have participated in a clinical trial of the HPV vaccine;
- •Has a history of cervical diseases, such as cervical screening showing abnormal results including CIN or a history of hysterectomy (vaginal or total abdominal hysterectomy) or pelvic radiation therapy. Has a history of genital diseases (such as vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, vulvar cancer, vaginal cancer and anal cancer, etc.) or has a previous sexual history (including syphilis, gonorrhea, chancre, venereal lymphatic granuloma, granuloma inguinal);
- •A history of severe allergies requiring medical intervention, such as anaphylactic shock, anaphylactic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), etc;
- •Subjects present with immune impairment or have been diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases. Long-term immunosuppressive therapy, e.g., long-term (more than 2 weeks) treatment with glucocorticoids (e.g., prednisone or similar drugs);
- •Has been diagnosed with a severe congenital malformation or chronic disease such as Down syndrome, heart disease, liver disease, kidney disease, diabetes, etc., which may interfere with the conduct or completion of the study;
- •Participating in other (drug or vaccine) clinical trials prior to enrollment or planning to participate during the study;
- •Has been diagnosed with an infectious disease, such as tuberculosis, viral hepatitis and/or HIV infection;
- •A history or family history of convulsions, epilepsy, encephalopathy and mental illness;
- •Have contraindications to intramuscular injection, such as having been diagnosed with thrombocytopenia, any coagulation disorder or receiving anticoagulant therapy;
- •Absence of a spleen, functional absence of a spleen, and absence or removal of a spleen in any case;
- •*Have an acute illness or an acute episode of a chronic illness within 3 days prior to vaccination or the use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.);
- •*Subjects received inactivated or recombinant vaccines within 14 days prior to study enrollment, or attenuated live vaccines within 28 days prior to study enrollment;
- •Subject receives any immunoglobulin or blood product within 3 months prior to the first dose of vaccination;
- •* after questioning, subjects had fever symptoms (subaxillary body temperature ≥37.3#) before the first day of vaccination (within 24 hours before vaccination);
- •Blood pressure on physical examination before the first dose of vaccination was higher than normal or increased (for subjects aged 16-17 year，systolic blood pressure ≥120mmHgand/or diastolic blood pressure ≥80mmHg，for subjects aged 18 year and above，systolic blood pressure ≥140mmHgand/or diastolic blood pressure ≥90mmHg);
- •Subjects may be unable to comply with the study procedure, comply with the agreement, or plan to permanently relocate from the region prior to completion of the study, or may be permanently absent from the region during the scheduled visit;
- •In the opinion of the investigators, the subjects had any other factors that made them unsuitable to participate in the clinical trial.
结局指标
主要结局
The seroconversion rate of neutralizing antibodies
时间窗: 30 days after the last dose
The seroconversion rate of neutralizing antibodies dected after immunization in pre-immune negative subjects from 30 days after the last dose HPV vaccine to HPV 6, 11, 16, 18, 31, 33, 45, 52 , and 58.
次要结局
- Number of SAE within 7days after each dose(day 0 to day 7 after each dose)
- Number of all SAE during the study period(Day 0 to 6 months post vaccination 3)
- The level of neutralizing antibody elicited by the vaccine among the subjects with pre-immune positive after the whole schedule vaccination(30 days after the last dose)
- Number of subjects with seroconversion rate (4-fold increase) after the whole schedule vaccination(30 days after the last dose)
- Number of AE within 30 minutes after each dose(30 mins after each dose)
- Number of unsolicited adverse events within 30days after each dose(day 0 to day 30 after each dose)
- Number and rate of pregnancy events(Day 0 to 6 months post vaccination 3)
- Number of subjects with postive antibodies after the whole schedule vaccination from the former negative subjects(30 days after the last dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesCervical CancerVaginal CancerCIN1CIN2CIN3VaIN1VaIN2VaIN3Genital WartVIN 1VIN 2VIN 3AISVulvar CancerNCT04425291Shanghai Bovax Biotechnology Co., Ltd.1,680
已完成
3 期
Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)Papillomavirus InfectionsNCT03903562Merck Sharp & Dohme LLC1,990
进行中（未招募）
3 期
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9Genital WartCINPapillomavirus InfectionsCervical CancerVINNCT05580341Shanghai Zerun Biotechnology Co.,Ltd1,200
招募中
3 期
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesCIN1CIN2CIN3VaIN1VaIN2Cervical CancerVaginal CancerVaIN3Genital WartVIN 1VIN 2VIN 3Vulvar CancerAISNCT04422366Shanghai Bovax Biotechnology Co., Ltd.8,000
进行中（未招募）
3 期
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese MalesGenital WartAnal CancerPIN-1PIN2PIN3AIN1AIN2AIN3HPV-Related CarcinomaPenile CancerNCT06465914Shanghai Bovax Biotechnology Co., Ltd.9,000